FRED HUTCHINSON CANCER CENTER
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00110058
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00107523
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
- Conditions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2010-09-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00107354
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Small Lymphocytic LymphomaProlymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaStage IV Chronic Lymphocytic LeukemiaT-Cell Large Granular Lymphocyte Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclosporineDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyBiological: RituximabRadiation: Total-Body Irradiation
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT00104858
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇩🇰Rigshospitalet University Hospital, Copenhagen, Denmark
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Conditions
- Previously Treated Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveWaldenstrom MacroglobulinemiaChildhood Myelodysplastic SyndromeStage II Contiguous Adult Diffuse Large Cell LymphomaStage II Contiguous Adult Lymphoblastic LymphomaStage II Grade 1 Contiguous Follicular LymphomaStage II Grade 2 Contiguous Follicular LymphomaStage II Non-Contiguous Adult Burkitt Lymphoma
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 210
- Registration Number
- NCT00105001
- Locations
- 🇩🇰
Rigshospitalet University Hospital, Copenhagen, Denmark
🇺🇸Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇩🇪Medizinische Univ Klinik Koln, Koln, Germany
Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2010-05-07
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00101257
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00098566
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00096161
- Locations
- 🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
🇮🇹University of Torino, Torino, Italy
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2010-05-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00096096
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00093366
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States